Last reviewed · How we verify

Dongkook Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Dongkook Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
DKF-306 DKF-306 marketed Other
DKF-313 DKF-313 phase 3 Unknown Unknown Unknown
DKF-MA102 DKF-MA102 phase 3 molecular target Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abdi Ibrahim Ilac San. ve Tic A.S. · 1 shared drug class
  2. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  3. Beijing Tiantan Hospital · 1 shared drug class
  4. Bursa Yuksek Ihtisas Training and Research Hospital · 1 shared drug class
  5. GlaxoSmithKline · 1 shared drug class
  6. Gloucestershire Hospitals NHS Foundation Trust · 1 shared drug class
  7. Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dongkook Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Dongkook Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dongkook-pharmaceutical-co-ltd. Accessed 2026-05-16.

Related